MEDIA_REFRESH_DATA_PRESS_RELEASE
Media
U.S. News Room
Press Releases
Tue Aug 06 00:00:00 GMT-05:00 2024
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070
Download
Thu Aug 01 00:00:00 GMT-05:00 2024
IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer
Download
Fri Jun 28 00:00:00 GMT-05:00 2024
Arbitration Dispute Between Daiichi Sankyo and Seagen Ends
Download
Wed Jun 26 00:00:00 GMT-05:00 2024
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
Download
Sun Jun 02 00:00:00 GMT-05:00 2024
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
Download
Mon May 27 00:00:00 GMT-05:00 2024
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Download
Tue May 21 00:00:00 GMT-05:00 2024
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
Download
Mon Apr 29 00:00:00 GMT-05:00 2024
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
Download
Fri Apr 05 00:00:00 GMT-05:00 2024
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
Download
Wed Apr 03 00:00:00 GMT-05:00 2024
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Download